Dendreon Overstated Demand For Provenge: Investors
Dendreon Corp. was hit with a shareholder class action in Washington federal court Monday that accuses executives of the Seattle-based biotechnology company of misleading investors about demand for its prostate cancer...To view the full article, register now.
Already a subscriber? Click here to view full article